Grail's cancer blood test faces high-stakes FDA review

A blood test to hunt signs of multiple cancers in healthy people is facing its first major U.S. regulatory hurdle. Federal health advisers meet Wednesday to recommend whether Grail Inc.'s test should be cleared for people 50 and older. It's the first time the technology has come before the Food and Drug Administration, which will make the final decision.…